Price$10.90+0.91 (+9.11%)
2026-04-212026-07-24
News · 26 weeks33-89%
2026-02-012026-07-26
Mix1690d
- Other7(44%)
- Insider7(44%)
- SEC Filings2(13%)
Latest news
25 items- PRDaxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, TexasDaxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy Oak Ridge, TN, July 07, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting for the first time at the 14th Annual Dysautonomia International Conference. Daxor will feature its FDA-cleared next-generation rapid, lightweight, lab-based Blood Volume Analyzer (BVA™). The premier global event for autonomic disorders will take place from July 9–12, 2026, at The Woodlands Marriott Waterway Hotel & Convention Center in The Woodlands, Texas. This year’s conference theme, "Piece by
- INSIDERChief Financial Officer Michel Robert J was granted 12,000 units of Daxor Common Stock, increasing direct ownership by 57% to 33,050 units (SEC Form 4)4 - DAXOR CORP (0000027367) (Issuer)
- INSIDERChief Executive Officer Feldschuh Michael Richard was granted 30,000 units of Daxor Common Stock, increasing direct ownership by 14% to 243,694 units (SEC Form 4)4 - DAXOR CORP (0000027367) (Issuer)
- INSIDERChief Scientific Officer Feldschuh Jonathan Adam was granted 25,000 units of Daxor Common Stock, increasing direct ownership by 46% to 78,908 units (SEC Form 4)4 - DAXOR CORP (0000027367) (Issuer)
- INSIDERSEC Form 4 filed by Director Goudie Joy S.4 - DAXOR CORP (0000027367) (Issuer)
- INSIDERSEC Form 4 filed by Director Cremisi Henry D.4 - DAXOR CORP (0000027367) (Issuer)
- INSIDERSEC Form 4 filed by Director Feuer Edward4 - DAXOR CORP (0000027367) (Issuer)
- INSIDERSEC Form 4 filed by Director Desrosiers Caleb4 - DAXOR CORP (0000027367) (Issuer)
- SECSEC Form 8-K filed by Daxor Corporation8-K - DAXOR CORP (0000027367) (Filer)
- SECAmendment: SEC Form 40-8F-2/A filed by Daxor Corporation40-8F-2/A - DAXOR CORP (0000027367) (Filer)
- SECSEC Form DEF 14A filed by Daxor CorporationDEF 14A - DAXOR CORP (0000027367) (Filer)
- PRDaxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume MonitorNew Technology Expands Daxor's Diagnostic Capabilities to Enable Continuous, Remote Tracking of Blood Volume Status Using Wearable Sensors, Enhancing Care for Heart Failure, Syncope, Anemia, and Polycythemia OAK RIDGE, TN, June 02, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,635,917 B2, titled "Remote Blood Volume Monitor." The newly issued patent covers innovative systems and methods for the ongoing and remote monitoring of a patient's absolute blood volume status after an initial baseline measurement. By integrat
- SECSEC Form NT NPORT-P filed by Daxor CorporationNT NPORT-P - DAXOR CORP (0000027367) (Filer)
- SECAmendment: SEC Form 40-8F-2/A filed by Daxor Corporation40-8F-2/A - DAXOR CORP (0000027367) (Filer)
- SECSEC Form 40-17F2 filed by Daxor Corporation40-17F2 - DAXOR CORP (0000027367) (Subject)
- PRDaxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume AnalysisOak Ridge, TN, April 28, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will exhibit its Blood Volume Analyzer (BVA™) technology at the MedAxiom CV Transforum Spring'26 Conference. The event, being held at the Sawgrass Marriott Golf Resort & Spa, Ponte Vedra Beach, FL, from April 30 – May 2, 2026, is a premier venue for cardiovascular thought leaders and industry innovators to drive the future of cardiac care delivery. The CV Transforum serves as a strategic touchpoint for Daxor to engage with high-level decision-makers and cardiovascular service line leaders. As hospitals increasingly shift toward valu
- INSIDERSEC Form 4 filed by Feldschuh Michael Richard4 - DAXOR CORP (0000027367) (Issuer)
- PRDaxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology CenterOak Ridge, TN, April 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, continues its strategic expansion with the launch of a new BVA program at a premier cardiology facility in Southwest Ohio. This integration brings Daxor's state-of-the-art testing to a high-volume heart failure care setting, targeting the growing market for chronic disease management. By leveraging Daxor's proprietary, Tennessee-based ezBVA Lab workflow, the facility gains access to 24-hour turnaround on gold-standard blood volume metrics without the need for onsite laboratory infrastructure. This "lab-as-a-service" model allows for rapid, data-driven
- SECAmendment: SEC Form N-CEN/A filed by Daxor CorporationN-CEN/A - DAXOR CORP (0000027367) (Filer)
- INSIDERSEC Form 4 filed by Michel Robert J4 - DAXOR CORP (0000027367) (Issuer)
- SECSEC Form 40-17F2 filed by Daxor Corporation40-17F2 - DAXOR CORP (0000027367) (Subject)
- PRDaxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces that new clinical data evaluating the accuracy of capillary leak detection scores compared to BVA was presented at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress. The study, titled, "Mechanistic Specificity of Capillary Leak Indices: Validation in Heart Failure as a Negative Control," was featured during the Research Snapshot Theater. The research investigated the relationship between traditional clinical scoring methods and direct, in-vivo measurement of albumin escape using Daxor's Blood Volume Analyzer (BV
- INSIDERSEC Form 4 filed by Jefferies John4 - DAXOR CORP (0000027367) (Issuer)
- PRDaxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced ReadmissionsOak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans, LA, March 28–30, 2026. Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA). As the only FDA-cleared diagnostic providing greater than 95% accurate, direct quantification of a patient's total blood, plasma, and red cell volume, the BVA replaces subjective guesswork with definitive data. This precision is a critical benefit of BVA, particularly for health systems navigating the $3.5 billion annua
- SECSEC Form N-CEN filed by Daxor CorporationN-CEN - DAXOR CORP (0000027367) (Filer)
DXR FAQ
5 questionsWhat does Daxor Corporation do?
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood...Where does DXR stock trade?
Daxor Corporation (DXR) is listed on AMEX.What sector and industry is DXR in?
Daxor Corporation operates in the Health Care sector, Medical/Dental Instruments industry.What companies are similar to DXR?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare DXR side-by-side with any of them on Quantisnow.How can I track DXR on Quantisnow?
Quantisnow aggregates Daxor Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DXR to receive live email and push alerts on every new disclosure.